Preparation and anticancer screening of liposomal formulation on HeLa and CT26 carcinoma cell line

  • Gaurav Gupta, Shelly Gupta, Mayank Gangwar

Abstract

Objective: The objective of the paper is to prepare and evaluate liposomal formulation against HeLa
and CT26 carcinoma cell line by MTT assay.
Material and methods: The non-targeted and targeted liposome formulations were prepared with
different composition of ingredients by thin film hydration technique. The liposomal formulation was
characterized for particle size, zeta potential, encapsulation efficiency, SEM and In-vitro release. The
liposome formulation with negative zeta potential used for the anticancer screening by ex-vivo study
on HeLa and CT-26 carcinoma cell line by MTT assay.
Result: The non targeted liposome formulation F5 has shown the particle size 187.23 nm with zeta
potential of -23.40 mV. The D-LP formulation has the particle size 142.23 nm with zeta potential of -
21.7 mV and Targeted liposome (F-D-LP) has shown the particle size 158.20 nm with zeta potential -
27.2 mV. The colon cancer cell line HeLa and CT26 were selected for anticancer screening by MTT
assay and result data suggested the IC50 for DOX, F5, D-LP and F-D-LP were 174.98, 170.54, 145.25
and 63.52 ?M, respectively in HeLa cell line. IC50 for DOX, F5, D-LP and F-D-LP were 22.91, 21.90,
18.54 and 4.02 ?M, respectively in CT-6 cell line.
Discussion: The Ex-vivo cytotoxicity study suggested that F-D-LP shown higher toxicity on HeLa and
CT-6 cell line as compare to DOX, F5 and D-LP. The growth inhibition effect of F-D-LP was
significantly stronger than DOX and non-targeted liposome (F5 and D-LP) on HeLa and CT-6 cell
line. DOX encapsulated in F-D-LP showed the lowest IC50, which means a significantly reduced dose
of drug in the targeted liposome with high effectiveness. The result concluded that targeted liposome
(F-D-LP) enhanced drug delivery and accumulation in cancer cells.

Published
2019-12-27
Section
Articles